Recursion Pharmaceuticals
clinical dosage hypothesis rescue of may impact tumor progression and or restore sensitivity in cancers driven by loss recursion differentiation rescues tumor suppressor genes and and are negative regulators of signaling both proteins form part of the destruction complex strong clustering suggests map recapitulation of this biology insight from novel insight around established | Recursion Pharmaceuticals
Company
Deck Type
Sector
Industry
Deck date
January 2023
Slide
116 of 143
Related slides by other companies
Mink Therapeutics
IPO
October 2021
phase clinical trial focused in solid tumors | Mink Therapeutics
Nuvalent
IPO
July 2021
planned first in human clinical trial of in positive and other advanced solid tumors | Nuvalent
Kymera
IPO
August 2020
degrader clinical development plan in liquid and solid tumors | Kymera
RayzeBio
IPO
September 2023
lead clinical indication refractory tumors nets tumors of the tract net and pancreas net have limited als gses | RayzeBio
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io